GR 2002
Alternative Names: GR-2002Latest Information Update: 06 Sep 2024
Price :
$50 *
At a glance
- Originator Genrix (Shanghai) Biopharmaceuticals
- Class Anti-inflammatories; Antiasthmatics; Antibodies; Skin disorder therapies
- Mechanism of Action Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Asthma; Atopic dermatitis
Most Recent Events
- 02 Jan 2024 Genrix (Shanghai) Biopharmaceutical completes a phase-I trial in Asthma (In volunteers) in China (SC) (NCT05954611)
- 21 Dec 2023 Genrix (Shanghai) Biopharmaceutical plans a phase I trial in Atopic dermatitis in China (SC) (NCT06175143)
- 28 Jul 2023 Phase-I clinical trials in Atopic dermatitis in China (SC) (before July 2023) (Genrix (Shanghai) Biopharmaceuticals Pipeline, July 2023)